Brawn Biotech Ltd
- Market Cap ₹ 5.10 Cr.
- Current Price ₹ 17.0
- High / Low ₹ 27.8 / 15.5
- Stock P/E
- Book Value ₹ 11.2
- Dividend Yield 0.00 %
- ROCE -42.5 %
- ROE -42.8 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Company has low interest coverage ratio.
- Company has a low return on equity of -23.5% over last 3 years.
- Working capital days have increased from 145 days to 216 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
34.42 | 38.65 | 46.88 | 59.78 | 55.71 | 65.18 | 49.62 | 34.98 | 8.53 | 22.23 | 16.49 | 13.47 | |
33.97 | 38.09 | 45.44 | 58.53 | 53.75 | 64.01 | 48.89 | 35.58 | 10.53 | 22.53 | 17.95 | 15.24 | |
Operating Profit | 0.45 | 0.56 | 1.44 | 1.25 | 1.96 | 1.17 | 0.73 | -0.60 | -2.00 | -0.30 | -1.46 | -1.77 |
OPM % | 1.31% | 1.45% | 3.07% | 2.09% | 3.52% | 1.80% | 1.47% | -1.72% | -23.45% | -1.35% | -8.85% | -13.14% |
-0.07 | 0.04 | 0.01 | 0.61 | 0.09 | 0.74 | 0.17 | 0.31 | 0.00 | 0.01 | 0.08 | 0.09 | |
Interest | 0.14 | 0.10 | 0.11 | 0.07 | 0.06 | 0.07 | 0.05 | 0.04 | 0.06 | 0.01 | 0.06 | 0.00 |
Depreciation | 0.01 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.05 | 0.11 | 0.10 | 0.11 |
Profit before tax | 0.23 | 0.47 | 1.31 | 1.76 | 1.96 | 1.81 | 0.82 | -0.36 | -2.11 | -0.41 | -1.54 | -1.79 |
Tax % | 39.13% | 40.43% | 27.48% | 20.45% | 34.69% | 26.52% | 28.05% | 55.56% | -22.27% | 109.76% | -19.48% | 0.00% |
0.14 | 0.28 | 0.95 | 1.39 | 1.28 | 1.33 | 0.59 | -0.55 | -1.64 | -0.87 | -1.25 | -1.80 | |
EPS in Rs | 0.47 | 0.93 | 3.17 | 4.63 | 4.27 | 4.43 | 1.97 | -1.83 | -5.47 | -2.90 | -4.17 | -6.00 |
Dividend Payout % | 0.00% | 0.00% | 31.58% | 32.37% | 23.44% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | -10% |
5 Years: | -23% |
3 Years: | 16% |
TTM: | -18% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -3% |
TTM: | -45% |
Stock Price CAGR | |
---|---|
10 Years: | 2% |
5 Years: | -10% |
3 Years: | 0% |
1 Year: | -36% |
Return on Equity | |
---|---|
10 Years: | -1% |
5 Years: | -18% |
3 Years: | -23% |
Last Year: | -43% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
Reserves | 1.68 | 1.94 | 2.53 | 3.92 | 4.63 | 5.66 | 6.26 | 5.79 | 4.22 | 3.31 | 2.06 | 0.36 |
0.01 | 0.11 | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
9.00 | 8.95 | 8.30 | 10.11 | 14.94 | 13.85 | 11.03 | 5.08 | 6.56 | 8.22 | 9.53 | 17.13 | |
Total Liabilities | 13.69 | 14.00 | 13.95 | 17.03 | 22.57 | 22.51 | 20.29 | 13.87 | 13.78 | 14.53 | 14.59 | 20.49 |
0.07 | 0.19 | 0.24 | 0.25 | 0.22 | 0.19 | 0.18 | 0.14 | 0.39 | 0.37 | 0.33 | 0.46 | |
CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.03 | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
13.59 | 13.78 | 13.68 | 16.78 | 22.35 | 22.32 | 20.11 | 13.73 | 13.39 | 14.16 | 14.26 | 20.03 | |
Total Assets | 13.69 | 14.00 | 13.95 | 17.03 | 22.57 | 22.51 | 20.29 | 13.87 | 13.78 | 14.53 | 14.59 | 20.49 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0.18 | 0.23 | 0.05 | 1.37 | -1.54 | 0.21 | -0.08 | 0.03 | 0.19 | 0.32 | -0.03 | 0.05 | |
-0.01 | -0.12 | -0.08 | 0.57 | 0.00 | 0.00 | -0.02 | 0.00 | -0.30 | -0.10 | -0.01 | -0.24 | |
-0.15 | 0.00 | -0.05 | -0.11 | -0.06 | -0.06 | -0.05 | -0.04 | -0.06 | -0.01 | 0.00 | 0.00 | |
Net Cash Flow | 0.02 | 0.11 | -0.08 | 1.83 | -1.60 | 0.15 | -0.14 | 0.00 | -0.17 | 0.21 | -0.04 | -0.20 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 88.65 | 87.07 | 71.63 | 79.50 | 98.60 | 92.17 | 110.34 | 96.83 | 120.24 | 87.35 | 85.88 | 92.40 |
Inventory Days | 22.14 | 11.17 | 4.50 | 2.59 | 2.62 | 2.12 | 3.38 | 3.16 | 261.82 | 91.20 | 153.02 | 320.33 |
Days Payable | 87.79 | 73.72 | 44.59 | 47.70 | 83.93 | 64.58 | 74.47 | 32.34 | 224.66 | 123.19 | 144.12 | 252.10 |
Cash Conversion Cycle | 23.01 | 24.52 | 31.54 | 34.39 | 17.29 | 29.72 | 39.25 | 67.65 | 157.41 | 55.36 | 94.78 | 160.63 |
Working Capital Days | 15.59 | 15.87 | 18.92 | 28.21 | 43.37 | 42.06 | 58.04 | 77.53 | 241.76 | 80.62 | 137.90 | 215.97 |
ROCE % | 24.89% | 11.91% | 26.54% | 29.28% | 27.77% | 23.08% | 9.71% | -3.55% | -25.61% | -5.91% | -25.86% | -42.52% |
Documents
Announcements
-
AFR For The Qtr/Year Ended 31St March 2025
28 May - Brawn Biotech reports audited FY25 financials with net loss; auditor gave unmodified opinion.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
28 May - Publication of financial results for the quarter/ year ended 31/03/2025
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
27 May - Brawn Biotech not required to file Annual Secretarial Compliance Report due to low capital and net worth.
-
AFR For The Quarter/ Year Ended 31/03/2025
26 May - Audited financial results for quarter and year ended March 31, 2025 approved and filed by Brawn Biotech.
-
Board Meeting Outcome for Outcome Of Board Meeting
26 May - Audited financial results for quarter and year ended March 31, 2025 approved by Board.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1][2]
Company is a fully integrated healthcare company having product registration with health and govt. institutions in India and abroad. It deals in Critical Care range of Products along with other Pharmaceutical products. Company's Pharmaceutical Formulations cover all major product segments viz. Anti-bacterial, Cardiovascular, Anti-diabetic, Analgesics, Gastrointestinal, Antifungals, Skin Care, Antipsychotics, Anti asthmatics, Antacids, Anti-malarial, and Nutritionals